Investigational Drug Information for tomivosertib
✉ Email this page to a colleague
What is the development status for investigational drug tomivosertib?
tomivosertib is an investigational drug.
There have been 6 clinical trials for tomivosertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 2nd 2021.
The most common disease conditions in clinical trials are Leukemia, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Effector Therapeutics, Stand Up To Cancer, and Translational Research in Oncology.
There are two US patents protecting this investigational drug and twenty-six international patents.
Summary for tomivosertib
| US Patents | 2 |
| International Patents | 26 |
| US Patent Applications | 38 |
| WIPO Patent Applications | 14 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2021-06-02) |
| Vendors | 47 |
Recent Clinical Trials for tomivosertib
| Title | Sponsor | Phase |
|---|---|---|
| Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy | National Cancer Institute (NCI) | Phase 1 |
| Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy | Northwestern University | Phase 1 |
| Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy | Medpace, Inc. | Phase 2 |
Clinical Trial Summary for tomivosertib
Top disease conditions for tomivosertib
Top clinical trial sponsors for tomivosertib
US Patents for tomivosertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| tomivosertib | ⤷ Subscribe | Inhibitors of immune checkpoint modulators and related methods | eFFECTOR Therapeutics Inc. (San Diego, CA) | ⤷ Subscribe |
| tomivosertib | ⤷ Subscribe | Methods and compositions for cellular immunotherapy | eFFECTOR Therapeutics Inc. (San Diego, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for tomivosertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| tomivosertib | Canada | CA3064000 | 2037-05-24 | ⤷ Subscribe |
| tomivosertib | World Intellectual Property Organization (WIPO) | WO2018218038 | 2037-05-24 | ⤷ Subscribe |
| tomivosertib | Australia | AU2015279984 | 2034-06-25 | ⤷ Subscribe |
| tomivosertib | Brazil | BR112016029916 | 2034-06-25 | ⤷ Subscribe |
| tomivosertib | Canada | CA2953365 | 2034-06-25 | ⤷ Subscribe |
| tomivosertib | Chile | CL2016003293 | 2034-06-25 | ⤷ Subscribe |
| tomivosertib | China | CN106795162 | 2034-06-25 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
